Results 161 to 170 of about 46,704 (314)

Extracellular Vesicles Derived From Mesenchymal Bone Marrow Cells Promote Antinociception in a Murine Model of Diabetic Neuropathy via the Endogenous Opioid System

open access: yesAdvanced Therapeutics, Volume 9, Issue 1, January 2026.
This study investigates the analgesic potential of extracellular vesicles derived from bone marrow mesenchymal stem cells (EV‐BMSC) in diabetic sensory neuropathy. EV‐BMSC reproduce the pain‐relieving effects of BMSC transplantation through opioid‐mediated mechanisms, highlighting a promising cell‐free therapeutic approach for neuropathic pain ...
Gessica S. A. Silva   +8 more
wiley   +1 more source

Morphine Tolerance Gated through EZH2‐Mediated Suppression of Trpc5 in Spinal GABAergic Interneurons in Male Mice

open access: yesAdvanced Science, Volume 13, Issue 1, 5 January 2026.
Chronic morphine suppresses Trpc5 in spinal GABAergic interneurons via EZH2‐mediated histone modification, reducing Ca2+ influx and GABA release. TRPC5 activation enhances morphine analgesia, while EZH2 inhibition restores efficacy and reverses tolerance.
Li Wan   +9 more
wiley   +1 more source

Antinociceptive and Cytotoxic Activity of Opioid Peptides with Hydrazone and Hydrazide Moieties at the C-Terminus. [PDF]

open access: yesMolecules, 2020
Dyniewicz J   +5 more
europepmc   +1 more source

Aptamer Engineering: Strategies for Discovering Functional Nucleic Acids for Next‐Generation Diagnostics and Biosensing

open access: yesAdvanced Science, Volume 13, Issue 2, 9 January 2026.
The advent of aptamers has highlighted their potential as alternatives to antibodies, overcoming limitations of structural instability and production cost. However, conventional approaches such as SELEX remain slow and labor‐intensive. This review examines recent advances in aptamer engineering, emphasizing in vitro and AI‐driven in silico strategies ...
John V. L. Nguyen   +5 more
wiley   +1 more source

Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 172-185, January 2026.
Aims Insomnia is a common sleep disorder, affecting up to 20% of the world population and adversely impacting productivity, health, and overall well‐being. Although pharmacologic options exist to treat insomnia, the health‐related quality of life for patients who are prescribed hypnotics is no higher than for those who are not, revealing a significant ...
Garth T. Whiteside   +5 more
wiley   +1 more source

Therapeutic Potential of Resveratrol in Cancer and Neurodegenerative Disorders: A Current Review

open access: yesBioFactors, Volume 52, Issue 1, January/February 2026.
Resveratrol induces the expressions of TP53, NRF2, and JDP2 axis in cancer cells to control ROS balance in mitochondria. The antioxidation responses were induced through SRIT1/3, HDAC, STAT3, TGFβ, and so on, to trigger the inflammation, and NFkB response to lead to the cell death of cancers or neuro‐damaged cells.
Kenly Wuputra   +9 more
wiley   +1 more source

Exploratory Pain Profiling With Quantitative Sensory Testing (QST) in Episodic and Chronic Migraine

open access: yesEuropean Journal of Pain, Volume 30, Issue 1, January 2026.
ABSTRACT Background Migraine pain profiling studies vary by sensory modalities, methods, anatomical sites and characteristics. This exploratory study aimed to identify pain profiling parameters using quantitative sensory testing (QST) for episodic migraine (EM) and chronic migraine (CM) and investigate potential differences, given conflicting results ...
Rein F. van Welie   +5 more
wiley   +1 more source

Opioid Peptide

open access: yesKobunshi, 1983
Hiroo Imura, Kazuwa Nakao
openaire   +2 more sources

Home - About - Disclaimer - Privacy